Healthcare -
Biotechnology - NASDAQ - US
$ 4.65
-9.71 %
$ 414 M
Market Cap
-1.05
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Amylyx Pharmaceuticals, Inc.
| Net Income | -302 M |
| Depreciation & Amortization | 904 K |
| Capital Expenditures | -157 K |
| Stock-Based Compensation | 33 M |
| Change in Working Capital | 0 |
| Others | 100 M |
| Free Cash Flow | -168 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (301.7) | 49.3 | (198.4) | (87.9) | (42.3) | (13.7) |
| Depreciation & Amortization | 0.9 | 1.1 | 0.5 | 52 K | 1 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0.1 | 1.0 | 0 |
| Stock Based Compensation | 33.0 | 37.2 | 21.7 | 3.1 | 0.2 | 0.1 |
| Other Operating Activities | 100.2 | (9.9) | (2.1) | 5.2 | 1.7 | (0.6) |
| Change in Working Capital | 0 | (65.7) | (1.6) | 4.6 | 2.6 | 3.5 |
| Cash From Operations | (167.6) | 11.9 | (179.9) | (74.8) | (36.7) | (10.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.2) | (1.2) | (2.5) | (0.4) | (0.2) | 0 |
| Other Items | 75.8 | 93.3 | (236.5) | (46.1) | 0 | 0 |
| Cash From Investing Activities | 75.7 | 92.1 | (239.0) | (46.4) | (0.2) | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | (3.3) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 25.9 | 16.8 | 0.6 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 3.5 | (0.7) | 132.6 | 30.0 | 27 K |
| Cash From Financing Activities | 0.3 | 3.5 | 431.8 | 158.5 | 46.8 | 0.7 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (92.1) | 107.7 | 12.9 | 37.3 | 10.0 | (10.0) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (167.8) | 10.7 | (182.4) | (75.2) | (36.8) | (10.7) |